Biond Biologics

Executive Summary

Biond Biologics is a clinical-stage Israeli biotech developing first-in-class immunotherapies for oncology and autoimmune diseases. Its core technology includes the INspire intracellular delivery platform and shedding-blocker biologics targeting immune evasion in solid tumors. The company's lead program, an anti-ILT3 antibody, aims to enhance antitumor immunity by blocking a novel immune checkpoint. In early 2026, Biond is expected to release initial Phase 1 safety and biomarker data for this program, which will be a key value inflection point. With a differentiated approach and a robust platform, Biond is positioned to address significant unmet needs, though it remains early-stage with typical development risks.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for anti-ILT3 antibody in solid tumors40% success
• Q4 2026Preclinical data for INspire platform or new pipeline candidate50% success
• Q2 2027Partnership or licensing deal for INspire platform30% success